Oncolytics Biotech To Present At Cancer Research Annual Meeting Apr. 10-15
Oncolytics Biotech To Present At Cancer Research Annual Meeting Apr. 10-15
SAN DIEGO and CALGARY, AB, March 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will present updated clinical data from its AWARE-1 window-of-opportunity study in patients with early-stage breast cancer, as well as results from preclinical studies evaluating pelareorep-based combination therapies, in poster presentations during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021.
Details on the posters and corresponding abstracts are shown below. All posters will be made available on the conference website on April 10, 2021.
海報和相應摘要的詳細內容如下所示。所有海報將於2021年4月10日在大會網站上公佈。
Title: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1)
Session Type: E-Poster Session
Session Category: Phase II Clinical Trials
Session Title: Phase II Clinical Trials
Abstract Number: CT191 (late-breaking abstract)
標題：在早期乳腺癌中應用阿替唑珠單抗和溶瘤病毒Pelareorep的機會窗研究(AWARE-1)會話類型：電子海報會議會話類別：第二階段臨牀試驗會話標題：第二階段臨牀試驗摘要編號：CT191(最新摘要)
Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding late-breaking abstracts.
Oncollytics公司將根據有關最新摘要的會議禁運政策，在4月份的AACR年會上發表摘要和相應的海報後，提供本摘要中描述的結果的細節。
Title: Mechanisms of therapeutic synergy between pattern recognition response agonists and cdk4 inhibitors
Session Type: E-Poster Session
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Cell Cycle
Abstract Number: 1960
標題：模式識別反應激動劑與CDK4抑制劑協同治療的機制會話類型：電子海報會議會話類別：分子和細胞生物學/遺傳學會話標題：細胞週期摘要編號： 1960
New preclinical studies identify the mechanisms of therapeutic synergy between pelareorep and the CDK4/6 inhibitor palbociclib. Data show that combining pelareorep with palbociclib augmented pelareorep-induced endoplasmic reticulum (ER) stress signaling and increased innate immune activation and effector function. These results suggest that this combination can be exploited to enhance anti-cancer efficacy with pro-immunogenic consequences and suggest that pelareorep may have the potential to broaden the therapeutic applicability of CDK4/6 inhibitors.
新的臨牀前研究確定了盆腔瑞普和CDK4/6抑制劑Palbociclib之間的治療協同作用的機制。數據顯示，聯合使用Pelarerep和Palbociclib可增強Pelareorep誘導的內質網(ER)應激信號，並增強先天免疫激活和效應功能。這些結果表明，這一組合可用於增強抗癌效果，並具有促進免疫原性的作用，並提示Pelareorep可能具有擴大CDK4/6抑制劑治療適用性的潛力。
The full text of the corresponding abstract is available on the AACR Annual Meeting 2021 website (link).
相應摘要全文可在AACR 2021年年會網站(鏈接).
Title: Talazoparib interacts with oncolytic reovirus to enhance death-inducing signaling complex (DISC)-mediated apoptosis and immune response
Session Type: E-Poster Session
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Apoptosis
Abstract Number: 1932
標題：他唑帕利與溶瘤呼腸孤病毒相互作用增強死亡誘導信號複合體(DISC)介導的細胞凋亡和免疫應答會話類型：電子海報會議會話類別：分子和細胞生物學/遺傳學會話標題：細胞凋亡摘要編號： 1932
New preclinical data show that combining pelareorep with talazoparib, a clinically approved poly(ADP)-ribose polymerase 1 (PARP-1) inhibitor, led to enhanced anti-tumor efficacy that correlated with an increased immune response in murine tumor models. These data provide a scientific rationale for combining pelareorep with PARP-1 inhibitors to exploit immunogenic responses in cancer treatment.
新的臨牀前數據顯示，與臨牀批准的聚(ADP)核糖聚合酶1(PARP-1)抑制劑他拉唑帕利聯合使用，可以增強抗腫瘤效果，這與增強小鼠腫瘤模型的免疫反應有關。這些數據為聯合Pareorep和PARP-1抑制劑以開發癌症治療中的免疫原性反應提供了科學依據。
The full text of the corresponding abstract is available on the AACR Annual Meeting 2021 website (link).
相應摘要全文可在AACR 2021年年會網站(鏈接).
About AWARE-1
AWARE-1 is an open label window-of-opportunity study in early-stage breast cancer enrolling 38 patients into five cohorts:
關於Aware-1Aware-1是一項針對早期乳腺癌的開放式標籤機會窗研究，將38名患者納入5個隊列：
- Cohort 1 (n=10), HR+ / HER2- (pelareorep + letrozole)
- Cohort 2 (n=10), HR+ / HER2- (pelareorep + letrozole + atezolizumab)
- Cohort 3 (n=6), TNBC (pelareorep + atezolizumab)
- Cohort 4 (n=6), HR+ / HER2+ (pelareorep + trastuzumab + atezolizumab)
- Cohort 5 (n=6), HR- / HER2+ (pelareorep + trastuzumab + atezolizumab)
- 隊列1(n=10)，HR+/HER2-(培拉羅普+來曲唑)
- 隊列2(n=10)，HR+/HER2-(Pelareorep+letrozole+atezolizumab)
- 隊列3(n=6)，TNBC(Pelareorep+atezolizumab)
- 隊列4(n=6)，HR+/HER2+(pelareorep+trastuzumab+atezolizumab)
- 隊列5(n=6)，HR-/HER2+(pelareorep+trastuzumab+atezolizumab)
The study combines pelareorep, with or without atezolizumab, and the standard of care therapy according to breast cancer subtype. Patients are biopsied as part of their initial breast cancer evaluation, then again on day three following initial treatment, and a final tissue sample after three weeks, on the day of their mastectomy. Data generated from this study are intended to confirm that the virus is acting as a novel immunotherapy and to provide comprehensive biomarker data by breast cancer subtype. The primary endpoint of the study is overall CelTIL (a measurement of cellularity and tumor-infiltrating lymphocytes). Secondary endpoints for the study include CelTIL by breast cancer subtype, safety and tumor, and blood-based biomarkers.
這項研究結合了培拉羅普，使用或不使用阿唑珠單抗，以及根據乳腺癌亞型的護理治療標準。作為最初乳腺癌評估的一部分，患者接受活檢，然後在最初治療後的第三天再次進行活檢，並在三週後的乳房切除當天進行最終組織樣本。這項研究產生的數據旨在證實該病毒正在作為一種新的免疫療法，並按乳腺癌亞型提供全面的生物標誌物數據。這項研究的主要終點是總體CelTIL(細胞密度和腫瘤浸潤性淋巴細胞的測量)。這項研究的次要終點包括乳腺癌亞型、安全性和腫瘤的CelTIL，以及基於血液的生物標記物。
For more information about the AWARE-1 study, refer to https://clinicaltrials.gov/ct2/show/NCT04102618.
有關-1\f25 Aware-1\f6研究的更多信息，請參閲Https://clinicaltrials.gov/ct2/show/NCT04102618.
譯文內容由第三人軟體翻譯。